小叶癌
免疫组织化学
病理
乳腺癌
浸润性小叶癌
医学
混乱
钙粘蛋白
癌
解剖病理学
导管癌
癌症
生物
浸润性导管癌
内科学
心理学
细胞
遗传学
精神分析
作者
David J. Dabbs,Stuart J. Schnitt,Felipe C. Geyer,Britta Weigelt,Frederick L. Baehner,Thomas Decker,Vincenzo Eusebi,Stephen B. Fox,Shu Ichihara,Sunil R. Lakhani,José Palacios,Emad A. Rakha,Andrea L. Richardson,Fernando Schmitt,Puay Hoon Tan,Gary M. Tse,Anne Vincent-Salomon,Ian O. Ellis,Sunil Badve,Jorge S. Reis-Filho
标识
DOI:10.1097/pas.0b013e3182918a2b
摘要
Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are most often identified in specimens taken for other reasons. Their incidence has increased in the last 2 decades, and novel variants, including a pleomorphic type, have been described. Loss of E-cadherin expression is recognized as a hallmark diagnostic feature of LN and invasive lobular carcinomas, and immunohistochemical (IHC) analysis using anti-E-cadherin antibodies has been proven to be a useful method to differentiate between lobular and ductal lesions. The frequent use of E-cadherin IHC analysis in routine diagnostic histopathology, however, has resulted in confusion with regard to the actual value of IHC with antibodies against E-cadherin and other proteins of the cadherin-catenin complex. This review provides an update on recent clinicopathologic and molecular data on LN and invasive lobular carcinoma and a discussion about the use and limitations of IHC with E-cadherin in diagnostic breast pathology.
科研通智能强力驱动
Strongly Powered by AbleSci AI